{"id":"rivastigmine-patch-9-5-cm2","safety":{"commonSideEffects":[{"rate":"10-15","effect":"Nausea"},{"rate":"5-10","effect":"Vomiting"},{"rate":"5-10","effect":"Diarrhea"},{"rate":"5-10","effect":"Abdominal pain"},{"rate":"5-10","effect":"Anorexia"},{"rate":"5-10","effect":"Dizziness"},{"rate":"5-10","effect":"Headache"},{"rate":"5-15","effect":"Application site erythema"}]},"_chembl":{"chemblId":"CHEMBL636","moleculeType":"Small molecule","molecularWeight":"250.34"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rivastigmine inhibits both acetylcholinesterase and butyrylcholinesterase, leading to increased concentrations of acetylcholine in the central nervous system. This enhancement of cholinergic neurotransmission helps improve cognitive function and behavioral symptoms in neurodegenerative diseases characterized by cholinergic deficits. The transdermal patch formulation provides continuous drug delivery over 24 hours.","oneSentence":"Rivastigmine is a cholinesterase inhibitor that increases acetylcholine levels in the brain by blocking the enzyme that breaks it down.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:30.715Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Mild to moderate Alzheimer's disease"},{"name":"Mild to moderate Parkinson's disease dementia"}]},"trialDetails":[{"nctId":"NCT00428389","phase":"PHASE3","title":"Safety of Switching From Donepezil to Rivastigmine Patch in Patients With Probable Alzheimer's Disease","status":"COMPLETED","sponsor":"Novartis","startDate":"2007-01","conditions":"Alzheimer's Disease","enrollment":262},{"nctId":"NCT00988117","phase":"PHASE4","title":"The Effects of the Rivastigmine Patch on Parkinson's Disease With Memory and/or Thinking Problems","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2010-04","conditions":"Parkinsons Disease With Dementia, Parkinsons Disease With Mild to Moderate Memory and/or Thinking Problems","enrollment":15},{"nctId":"NCT00948766","phase":"PHASE4","title":"Effects of Rivastigmine Patch on Activities of Daily Living and Cognition in Patients With Severe Dementia of the Alzheimer's Type (ACTION) (Study Protocol CENA713DUS44, NCT00948766) and a 24 Week Open-label Extension to Study CENA713DUS44","status":"COMPLETED","sponsor":"Novartis","startDate":"2009-07","conditions":"Alzheimer's Disease","enrollment":716},{"nctId":"NCT00623103","phase":"PHASE3","title":"Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-01","conditions":"Parkinson's Disease Dementia","enrollment":583}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Rivastigmine Patch 9.5 cm2","genericName":"Rivastigmine Patch 9.5 cm2","companyName":"University of California, San Francisco","companyId":"university-of-california-san-francisco","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rivastigmine is a small molecule inhibitor of cholinesterases, specifically targeting ACHE and BCHE. It is used to treat conditions such as Alzheimer's Disease, Parkinson's Disease With Dementia, and Parkinson's Disease With Mild to Moderate Memory and/or Thinking Problems, among others.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}